Unknown

Dataset Information

0

Autophagy Inhibitors Do Not Restore Peroxisomal Functions in Cells With the Most Common Peroxisome Biogenesis Defect.


ABSTRACT: Peroxisome biogenesis disorders within the Zellweger spectrum (PBD-ZSDs) are most frequently associated with the c.2528G>A (p.G843D) mutation in the PEX1 gene (PEX1-G843D), which results in impaired import of peroxisomal matrix proteins and, consequently, defective peroxisomal functions. A recent study suggested that treatment with autophagy inhibitors, in particular hydroxychloroquine, would be a potential therapeutic option for PBD-ZSD patients carrying the PEX1-G843D mutation. Here, we studied whether autophagy inhibition by chloroquine, hydroxychloroquine and 3-methyladenine indeed can improve peroxisomal functions in four different cell types with the PEX1-G843D mutation, including primary patient cells. Furthermore, we studied whether autophagy inhibition may be the mechanism underlying the previously reported improvement of peroxisomal functions by L-arginine in PEX1-G843D cells. In contrast to L-arginine, we observed no improvement but a worsening of peroxisomal metabolic functions and peroxisomal matrix protein import by the autophagy inhibitors, while genetic knock-down of ATG5 and NBR1 in primary patient cells resulted in only a minimal improvement. Our results do not support the use of autophagy inhibitors as potential treatment for PBD-ZSD patients, whereas L-arginine remains a therapeutically promising compound.

SUBMITTER: Klouwer FCC 

PROVIDER: S-EPMC8047214 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5210156 | biostudies-literature
| S-EPMC5446072 | biostudies-literature
| S-EPMC3795339 | biostudies-literature
| S-EPMC6606614 | biostudies-literature
| S-EPMC8386603 | biostudies-literature
| S-EPMC86304 | biostudies-literature
| S-EPMC3844471 | biostudies-literature
| S-EPMC1169612 | biostudies-other
| S-EPMC2289127 | biostudies-other
| S-EPMC8077185 | biostudies-literature